The increasing adoption of combination drug therapies is anticipated to openup the new avanue for Leishmaniasis Treatment Market

The increasing adoption of combination drug therapies is anticipated to openup the new avanue for Leishmaniasis Treatment Market

Market Overview:
Leishmaniasis is a vector-borne disease caused by Leishmania protozoan parasites. It is transmitted through the bite of infected female sand flies. The disease presents itself in three main forms: cutaneous, mucocutaneous, and visceral leishmaniasis. Treatment involves use of drugs like miltefosine, amphotericin B and paromomycin. Combination therapies using drugs like miltefosine and liposomal amphotericin B are also being increasingly adopted.

Market Dynamics:
One of the primary drivers fueling growth of the leishmaniasis treatment market is increasing research efforts towards development of novel and more effective drugs. For instance, drugs like Bryostatin-1 and ectonucleoside triphosphate diphosphohydrolase-4 (ENTPDase4) inhibitors are under clinical trials. Bryostatin-1 modulates host immunity and ENTPDase4 inhibitors target adenylate cyclase of Leishmania parasites. Increasing prevalence of leishmaniasis globally due to factors such as rising temperatures, population growth and urbanization is another major driver. As per WHO, around 1.3 million new cases and over 30,000 deaths are reported worldwide annually due to leishmaniasis. Developing regions such as Asia, Africa, Latin America and Middle East bear over 90% of the global disease burden.
Segment Analysis
The global Leishmaniasis Treatment Market Demand is dominated by the systemic segment which accounts for over 60% of total market share. This is because systemic drugs are most widely used for treating both visceral and cutaneous forms of leishmaniasis. Antifungal and antileishmanial drugs dominates the systemic treatment segment due to high efficacy and tolerability against leishmania parasites.

PEST Analysis
Political: Governments globally are increasing support for research and development of novel treatment options for leishmaniasis due to rising disease prevalence. Economic: Higher disease burden translating to increased healthcare expenditure is expected to boost market revenues. However, low diagnosis rates in developing nations can hamper market growth. Social: Rising awareness may enhance early diagnosis and treatment seeking rate. Technological: Focus on development of combination therapies, drug delivery enhancement, and vaccines to address resistance and compliance issues.

Key Takeaways
The global leishmaniasis treatment market size was valued at US$ 69.4 million in 2023. The market is expected to witness high growth, exhibiting a CAGR of 4.4% over the forecast period, due to expanding patient pool across developing regions.

Regional analysis: Asia Pacific region currently dominates the market and is estimated to grow at fastest pace during the analysis period attributed to large patient base in countries like India. High incidence of visceral leishmaniasis cases makes India a prime market for treatment manufacturers.

Key players operating in the leishmaniasis treatment market are Knight Therapeutics, gland pharma, Sanofi, Novartis, GloxoSmithKline, Pfizer, Cheplapharm Arzneimittel GmbH and Jassen Pharmaceutical. Key players are focusing on developing advanced technologies such as combination therapies and long-acting dosage forms to improve patient compliance.
Read More:

https://www.pressreleasebulletin.com/leishmaniasis-treatment-market-is-estimated-to-witness-high-growth/